SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Summit Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 23, 2026
$15.57+0.94 (+6.43%)
Close on Oct 19, 2026
- Market cap
- $12.12B
- P/E (TTM)
- –
- Dividend yield
- –
Summit Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Summit Therapeutics | Industry median |
|---|---|---|
| Market Cap | $12.42B | $166.30M |
| Enterprise Value | $11.73B | $88.19M |
| PB Ratio | 19.72 | 2.03 |
| P/TBV Ratio | 19.78 | 2.29 |
Income (trailing twelve months)
| Measure | Summit Therapeutics | Industry median |
|---|---|---|
| Net Income | -$856.09M | -$22.46M |
| EPS (Diluted) | -$1.12 | -$0.83 |
Returns
| Measure | Summit Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -192.5% | -53.2% |
| Return on Assets (ROA) | -159.1% | -40.9% |
Balance sheet
| Measure | Summit Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $690.68M | $61.43M |
| Net Cash (Debt) | $690.68M | $15.35M |
| Net Cash Per Share | $0.87 | $0.66 |
| Equity (Book Value) | $629.98M | $49.09M |
| Book Value Per Share | $0.79 | $1.37 |
| Tangible Book Value | $628.02M | $23.52M |
| Working Capital | $617.01M | $76.81M |
Financial position
| Measure | Summit Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.96 | 3.34 |
| Quick Ratio | 6.67 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Summit Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$458.43M | -$12.35M |
| Capital Expenditures | -$1.39M | -$1.08M |
| Free Cash Flow | -$459.82M | -$20.22M |
| FCF Per Share | -$0.58 | -$0.42 |
Efficiency
| Measure | Summit Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$3.23M | -$703.34K |
| Employee Count | 265 | 74 |
Dividends and yields
| Measure | Summit Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -6.89% | -23.3% |
| FCF Yield | -3.70% | -8.72% |
Shares
| Measure | Summit Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 797,750,000 | 58,127,000 |
| Shares Change (YoY) | 4.03% | 10.9% |
| Shares Change (QoQ) | 2.20% | 0.54% |
| Shares Held by Institutions | 17.0% | 59.4% |
Scores
| Measure | Summit Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 56.95 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Summit Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.